Características inmunológicas claves en la fisiopatología de la sepsis
Infectio · 2015
DOI: 10.1016/j.infect.2014.03.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infectio, 2015. Verfasst von Henry Geovanni Gomez und 2 weiteren Autor:innen. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 3.0).
Themen: Sepsis
Abstract (Originalsprache)
Despite our current understanding of sepsis pathophysiology, this disease is still a leading cause of death worldwide. Forty percent of patients admitted to intensive care units develop this illness, and 20 to 50% of septic patients die due to its associated complications. Current research aims to improve our understanding of the cellular and molecular mechanisms of this disease and translate these findings into clinical applications that provide a better prognosis for these patients. Currently, it is believed that a susceptible host develops a systemic inflammatory response syndrome (SIRS) after an encounter with a pathogen; however, some individuals progress to a state of immunoparalysis known as compensatory anti-inflammatory response syndrome (CARS), which has been associated with secondary infections. The purpose of the present review is to highlight the main features of sepsis pathophysiology and to highlight the clinical implications of basic research from an immunological perspective.
Zitieren
APA
Gomez, H. G., Rugeles, M. T., & Jaimes, F. A. (2015). Características inmunológicas claves en la fisiopatología de la sepsis. Infectio. https://doi.org/10.1016/j.infect.2014.03.001
Vancouver
Gomez HG, Rugeles MT, Jaimes FA. Características inmunológicas claves en la fisiopatología de la sepsis. Infectio. 2015. doi:10.1016/j.infect.2014.03.001
BibTeX
@article{Gomez2015,
author = {Gomez, Henry Geovanni and Rugeles, María Teresa and Jaimes, Fabián Alberto},
title = {Características inmunológicas claves en la fisiopatología de la sepsis},
journal = {Infectio},
year = {2015},
doi = {10.1016/j.infect.2014.03.001}
}
EUVIMED